Document is current
Any future updates will be listed below
-
Authors
Lallas, Konstantinos
Kittler, Harald https://orcid.org/0000-0002-0051-8016
Tschandl, Philipp https://orcid.org/0000-0003-0391-7810
Liopyris, Konstantinos
Amaral, Teresa
Argenziano, Giuseppe https://orcid.org/0000-0003-1413-8214
Bakos, Renato Marchiori
Braun, Ralph
Cabo, Horacio
Dika, Emi https://orcid.org/0000-0003-3186-2861
Malvehy, Josep https://orcid.org/0000-0002-6998-914X
Marghoob, Ashfaq https://orcid.org/0000-0001-6068-0114
Puig, Susana https://orcid.org/0000-0003-1337-9745
Scope, Alon
Stolz, Wilhelm https://orcid.org/0000-0002-4515-9395
Minagawa, Akane
Costa, Manuela Martins
Agozzino, Marina
Shalmon, Dana
Briatico, Giulia
Cohen Sabban, Emilia Noemi
Mar, Victoria https://orcid.org/0000-0001-9423-3435
Mahon, Clare
Muller, Nicholas M. https://orcid.org/0000-0002-6294-4109
Tanaka, Masaru
Liu, Timothy https://orcid.org/0000-0002-8034-9856
Pham, Felix https://orcid.org/0000-0002-7855-4930
Alessandrini, Aurora
Chamberlain, Alex
Vico-Alonso, Cristina
Thomas, Luc https://orcid.org/0000-0003-1995-2434
Soyer, H. Peter https://orcid.org/0000-0002-4770-561X
Apalla, Zoe
Vakirlis, Efstrations
Zalaudek, Iris
Lallas, Aimilios https://orcid.org/0000-0002-7193-0964
- License Information
-
More Information
Article History
Received: 14 May 2025
Accepted: 27 October 2025
First Online: 8 December 2025
Competing interests
: TA- TA reports personal fees for advisory board membership from Delcath and Philogen; personal fees as an invited speaker from Bristol Myers Squibb (BMS), Medscape, Neracare, Novartis and Pierre Fabre; personal fees for a writing engagement from CeCaVa and Medtrix; institutional fees as local principal investigator (PI) from Agenus Inc., AstraZeneca, BioNTech, BMS, HUYA Bioscience, Immunocore, IO Biotech, MSD, Pfizer, Philogen, Regeneron, Roche and University Hospital Essen; institutional fees as coordinating PI from Unicancer; institutional research grants from iFIT and Novartis; institutional funding from MNI - Naturwissenschaftliches und Medizinisches Institut, Neracare, Novartis, Pascoe, Sanofi and Skyline-Dx; non-remunerated membership of the American Society of Clinical Oncology (ASCO) and the Portuguese Society for Medical Oncology; a role as clinical expert in the area of medical oncology for Infarmed, and a role as an expert for SGA-Oncology at EMA. These activities had no role in the study’s design, data acquisition, results interpretation and decision to submit. HPS- HPS is a shareholder of MoleMap NZ Limited and e-derm consult. GmbH and undertakes regular teledermatological reporting for both companies. HPS is a Medical Consultant for Canfield Scientific Inc and a Medical Advisor for First Derm. These activities had no role in the study’s design, data acquisition, results interpretation and decision to submit. All remaining authors have declared no conflicts of interest.
